The Risks of Over-Promising in Early-Stage Biologics Development

In the competitive world of biologics development, bold projections can be as valuable as the science itsel, especially when early-stage ventures are seeking funding, partners, and internal buy-in. But when expectations exceed the scientific or operational reality, the result can be costly: both financially and reputationally.

Over-promising in biologics R&D typically refers to making claims about therapeutic potential, development timelines, or manufacturability that are not fully substantiated by data. While optimism and ambition are essential to innovation, disconnects between what is promised and what is feasible often derail even the most promising programs.

In this article, we explore the root causes behind over-promising in early biologics development, the risks that arise from it, and how teams can adopt more realistic and data-driven communication from the start.

Why Over-Promising Happens in Biologics Development

The early stages of biologics development are marked by both hope and uncertainty. Across the industry, several systemic pressures contribute to overstatement. Some of them are strategic, others psychological in nature.

Investor and Market Pressure

Securing funding is often tied to pipeline potential. Start-ups and early-stage ventures are incentivized to showcase confidence in their programs, especially in investor presentations or press releases. Announcements of strong preclinical data or imminent clinical milestones are sometimes made before key stability, scalability, or safety risks are fully assessed ¹. 

With the global antibody market size estimated to be worth around 266.83 billion in 2024, this tendency is exacerbated by a crowded landscape in which companies compete for both market share and visibility ².

Scientific Optimism Bias

Biologics developers, like all scientists, are prone to optimism bias. Early in development, researchers may assume that strong in vitro or animal model data will translate smoothly into clinical outcomes. 

In reality, many candidates falter in the transition to human trials due to unforeseen immunogenicity, instability, or delivery challenges ³. Over-reliance on preclinical “successes” can mask the complexity of therapeutic translation ⁴.

Communication Gaps Within Cross-Functional Teams

Another common source of over-promising lies in the siloed nature of biologics R&D. Research teams may identify a high-affinity antibody and interpret it as a viable therapeutic, while manufacturing, formulation, or regulatory experts may not yet have assessed its stability, scalability, or immunogenicity profile ⁵. 

Without integrated risk assessments, early communications can reflect an overly simplified view of what lies ahead ⁶.

Risks of Over-Promising in Early Development

Over-promising can have tangible downstream consequences across science, strategy, and reputation. These are the most common risks to consider:

Scientific Risks

Perhaps most critically, over-promising distorts the scientific process. By prematurely prioritizing unvalidated candidates or accelerating timelines, teams risk bypassing essential optimization steps. 

Promising efficacy that cannot be replicated, or failing to flag known limitations, can result in wasted development resources and failed clinical programs ⁷. The consequences are not only financial: patient safety may also be at stake ⁸.

Strategic and Financial Risks

From a business perspective, unmet projections can lead to reduced investor confidence, funding shortfalls, and even program de-prioritization. In an environment where timelines are scrutinized and resources are finite, failing to deliver on expectations often forces a pipeline reset and delaying other candidates in the process ⁹. 

In some cases, public or partner-facing promises can become liabilities in valuation assessments or future fundraising rounds ¹⁰.

Reputational Risks

Over-promising also undermines trust within the scientific community and among stakeholders. Whether it’s overstated preclinical data or timelines that consistently shift, credibility is hard to regain once lost. 

For companies reliant on strategic collaborations, licensing deals, or co-development partnerships, this can significantly reduce attractiveness as a partner ¹¹.

Strategies to Avoid Over-Promising

Given the risks, a key objective in early biologics development should be to align internal and external communication with data-informed, realistic projections.

Implementing Robust Go/No-Go Criteria

Clear, pre-defined decision points help teams remain grounded. These criteria should include assessments of developability, manufacturability, safety risks, and stability, not just efficacy. Antibody candidates that fail to meet thresholds in these areas should be redesigned or deprioritized, not advanced prematurely ¹².

Cross-Functional Risk Assessments

Risk should be assessed collaboratively, with R&D, manufacturing, and regulatory perspectives equally represented. This allows for earlier identification of bottlenecks, such as expression yield limitations or formulation sensitivities, that could compromise success down the line ¹³.

Transparent, Evidence-Based Communication

Internal and external messaging should reflect the actual development stage, available data, and anticipated challenges. When discussing pipeline progress with investors, stakeholders, or collaborators, it’s better to underscore the plan to address risks than to ignore them entirely. This builds trust and demonstrates strategic maturity.

How evitria Helps Manage Realistic Expectations

At evitria ¹⁴, we understand that early development decisions have long-term impact. Our recombinant antibody production service is designed to empower biologics developers with reliable data and expert insights, so that expectations can be managed realistically and success planned strategically.

• Providing Rapid, Reproducible Data: Our CHO-based expression systems allow for fast, parallel evaluation of multiple antibody candidates. High reproducibility across formats enables early comparisons of expression yield, solubility, and basic stability. These are key indicators of developability that guide go/no-go decisions.
• Expertise in Manufacturability and Stability Assessments: We offer insights into processability, formulation tolerance, and structural liabilities, helping teams identify potential hurdles before scale-up. Our clients benefit from decades of antibody production experience, including glycoengineering and Fc modifications that support half-life extension and enhanced stability.
• Partnership Approach: We work as an extension of your R&D team, offering not just services, but strategic consultation. Whether you need stability data for stakeholder communication or want to test manufacturability scenarios early, we’re here to support a development process built on realism and scientific rigor ¹⁵.

References

1. Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development. Rare Diseases and Orphan Products: Accelerating Research and Development. Edited by Marilyn J. Field and Thomas F. Boat, National Academies Press (US), 2010. https://www.ncbi.nlm.nih.gov/books/NBK56179/. ↩︎
2. Future Market Insights. Antibodies Market Outlook (2023 to 2033). https://www.futuremarketinsights.com/reports/antibodies-market. ↩︎
3. Ecker, Dawn M et al. “The therapeutic monoclonal antibody market.” mAbs vol. 7,1 (2015): 9-14. doi:10.4161/19420862.2015.989042 ↩︎
4. Lu, Ruei-Min et al. “Development of therapeutic antibodies for the treatment of diseases.” Journal of biomedical science vol. 27,1 1. 2 Jan. 2020, doi:10.1186/s12929-019-0592-z ↩︎
5. Al-Showbaki, Laith et al. “Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies.” The oncologist vol. 27,6 (2022): 487-492. doi:10.1093/oncolo/oyac031 ↩︎
6. Jansen, Lynn A. “The optimistic bias and illusions of control in clinical research.” IRB: Ethics & Human Research 38.2 (2016): 8-14. ↩︎
7. Madsen, Andreas V et al. “Design and engineering of bispecific antibodies: insights and practical considerations.” Frontiers in bioengineering and biotechnology vol. 12 1352014. 25 Jan. 2024, doi:10.3389/fbioe.2024.1352014 ↩︎
8. Beck, Alain, et al. “Strategies and challenges for the next generation of therapeutic antibodies.” Nature reviews immunology 10.5 (2010): 345-352. ↩︎
9. Chames, Patrick et al. “Therapeutic antibodies: successes, limitations and hopes for the future.” British journal of pharmacology vol. 157,2 (2009): 220-33. doi:10.1111/j.1476-5381.2009.00190.x ↩︎
10. Chapman, K., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, , J.Robinson, V. (2009). Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates. mAbs, 1(5), 505–516. https://doi.org/10.4161/mabs.1.5.9676 ↩︎
11. Chen, C., Garcia, Z., Chen, D., Liu, H., & Trelstad, P. (2025). Cost and supply considerations for antibody therapeutics. mAbs, 17(1). https://doi.org/10.1080/19420862.2025.2451789 ↩︎
12. Kelley, Brian et al. “Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products.” Current opinion in biotechnology vol. 78 (2022): 102798. doi:10.1016/j.copbio.2022.102798 ↩︎
13. Wang, Qiong et al. “Design and Production of Bispecific Antibodies.” Antibodies (Basel, Switzerland) vol. 8,3 43. 2 Aug. 2019, doi:10.3390/antib8030043 ↩︎
14. evitria. “bYlok® Technology.” https://www.evitria.com/journal/bylok-technology/. evitria. “Antibody Discovery.” https://www.evitria.com/antibodies/antibody-discovery/. ↩︎
15. National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies. Monoclonal Antibody Production. Washington (DC): National Academies Press (US); 1999. 5, “Large-Scale Production of Monoclonal Antibodies”. URL: https://www.ncbi.nlm.nih.gov/books/NBK100189/. Last accessed July 8, 2025. ↩︎